SCHEMBL6408764

SCHEMBL6408764

CC(C)(C)[CH]c1nnc(-c2cc(Cl)nc(Cl)c2)o1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33
ACHE P22303 1/20 0.32
BACE1 P56817 1/20 0.32
BRD4 O60885 1/20 0.32
HPGD P15428 4/20 0.32
METAP2 P50579 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
PTGS1 P23219 1/20 0.31
PTGS2 P35354 1/20 0.31
ALDH1A1 P00352 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
S1PR1 P21453 1/20 0.31
NOTUM Q6P988 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6402526 0.76 BCHE (0.39) KDM4ECYP1A2CYP3A4MAPTCYP2C9
SCHEMBL6403740 0.73 PKM (0.57) KDM4ECYP1A2CYP3A4MAPTCYP2C9
SCHEMBL6405806 0.69 HPGD (0.38) KDM4EMAPTHPGDNPC1RAB9A
SCHEMBL6408020 0.69 HPGD (0.38) KDM4EMAPTHPGDNPC1RAB9A
SCHEMBL2743753 0.60 S1PR2 (0.42) KDM4EHPGDSMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL6406903 0.59 NOTUM (0.55) KDM4EMAPTHPGDALDH1A1NOTUM
SCHEMBL14363655 0.57 ACHE (0.52) MAPTACHENPC1RAB9AS1PR1
SCHEMBL13609458 0.57 PTGS1 (0.42) KDM4ECYP1A2BRD4HPGDNPC1
SCHEMBL18485581 0.57 KDM4E (0.48) KDM4EMAPTNPC1RAB9AS1PR1
SCHEMBL21777028 0.57 NOTUM (0.57) KDM4ECYP1A2MAPTACHEBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050107616-A1 Alpha-ketoamide derivatives as cathepsin k inhibitors SMITHKLINE BEECHAM CORPORATION 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107616-A1 Alpha-ketoamide derivatives as cathepsin k inhibitors CTSK, CTSE, CTSZ KDM4E 258/4885CYP1A2 1519/4885CYP3A4 2174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.